Baseline LV dysfunction did not affect survival after TAVR but was associated with increased cardiac mortality at 1 year with standard therapy ( 59.3 % vs 45.8 % with normal LVEF ; HR = 1.71 ( 95 % CI 1.08 to 2.71 ) ; p = 0.02 ) .